The Alzheimer’s community is eagerly awaiting a decision from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) regarding the approval of lecanemab, a promising drug designed to slow the progression of the disease.
Developed by pharmaceutical giants Eisai and Biogen, a new Alzheimer’s drug – lecanemab – has already gained significant attention after receiving approval from the U.S. Food and Drug Administration (FDA) earlier this year.
However, a recent setback occurred when the European Medicines Agency (EMA) rejected the drug’s application, citing insufficient evidence of its effectiveness. This decision has cast a shadow over the potential of lecanemab to become a widely available treatment for Alzheimer’s disease.
Lecanemab operates by targeting and reducing amyloid beta plaques in the brain, which are believed to contribute to the development of Alzheimer’s. While clinical trials in the United States demonstrated modest cognitive benefits for people in the early stages of the disease, the EMA’s stringent evaluation criteria were not met.
The MHRA is now carefully considering the available data on lecanemab before making its own determination. The agency’s decision will have profound implications for people living with Alzheimer’s and their families in the UK, as well as for the broader global research community.
Alzheimer’s disease is a progressive condition affecting millions of people worldwide. There is currently no cure, and the search for effective treatments remains a top priority. The outcome of the MHRA’s review will be closely watched by people living with dementia, people who support them, and healthcare professionals alike.
Read the full BBC article here.
If you, or your team, would like to learn more about providing the best, person-centred care to those you support who are living with Dementia, our Dementia courses are a great place to start. Take a look at our full course list here: Dementia Training Courses – Coleman Training.